20cm速递｜创业板医药ETF国泰（159377）涨超2.2%，脑机接口与创新器械成焦点

Group 1 - The core focus of the news is on the performance of the ChiNext Medical ETF (159377), which rose over 2.2%, highlighting the significance of brain-computer interfaces and innovative medical devices [1] - The development of pan-RAS/KRAS inhibitors aims to cover a broader range of mutation types and potentially overcome resistance issues more effectively, with KRAS mutations being the most prevalent in human cancers at 81% [1] - The CXO and upstream sectors are experiencing slight growth in pharmaceutical financing, with factors such as BD transactions and H-share IPOs revitalizing innovation enthusiasm, leading to a recovery in order demand [1] Group 2 - The ChiNext Medical ETF tracks the Innovation Medicine Index (399275), which includes listed companies in the biopharmaceutical and medical device sectors, reflecting the overall performance of China's healthcare industry in innovation [2] - The index has a daily price fluctuation limit of 20%, and it encompasses companies involved in innovative drug development, biotechnology, and medical services [2]